Pfizer Receives Multiple Regulatory Approvals for Cancer and Hemophilia Therapies

Pfizer announced several regulatory approvals, including FDA approval for IBRANCE® for HR+, HER2+ breast cancer maintenance treatment and PADCEV® plus Keytruda® for muscle-invasive bladder cancer, marking the first platinum-free regimen for this condition. Additionally, the European Commission expanded the approved indication for HYMPAVZI® for hemophilia A or B in patients aged 12 and older. These approvals provide new treatment options across multiple therapeutic areas.